echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hansen Pharma submits Phase III clinical trial application for the treatment of mycotic vaginitis

    Hansen Pharma submits Phase III clinical trial application for the treatment of mycotic vaginitis

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On September 13, Hansen Pharmaceuticals (Hausen Pharmaceuticals, 3692.
    HK) announced that ibrexafungerp, which has rights in the Greater China region, has submitted a Phase III clinical trial application to the National Medical Products Administration (NMPA) for the treatment of mold.
    Sexual vaginitis


    As early as February 11 this year, Hansen Pharmaceuticals announced that it had entered into an exclusive license and cooperation agreement with SCYNEXIS, Inc.

    According to the license agreement, the licensee Hansen Pharmaceuticals will obtain the exclusive license of SCYNEXIS to research, develop and commercialize ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan)

    As a consideration for the exclusive franchise, the licensee agreed to pay SCYNEXIS a down payment of US$10 million plus potential milestone payments and commissions


    On June 2, 2021, ibrexafungerp (trade name: BREXAFEMME) was approved by the U.
    Food and Drug Administration (FDA)


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.